NVELOP Trademark

Trademark Overview


On Wednesday, July 5, 2023, a trademark application was filed for NVELOP with the United States Patent and Trademark Office. The USPTO has given the NVELOP trademark a serial number of 98072031. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Saturday, July 13, 2024. This trademark is owned by Nvelop Therapeutics, Inc.. The NVELOP trademark is filed in the Pharmaceutical Products, Medical Instrument Products, and Computer & Software Services & Scientific Services categories with the following description:

pharmaceutical preparations for gene therapy and gene editing; drug delivery agents that facilitate delivery of pharmaceuticals, namely, drug delivery agents consisting of particles that facilitate delivery of a wide range of pharmaceuticals; drug carriers for medical use, namely, drug delivery agents in the form of engineered particles that facilitate the delivery of pharmaceutical preparations for delivering drugs to human organs; cell and gene therapy products for increasing protein expression in cells namely, engineered particles; pharmaceutical and biological preparations for delivering proteins into cells for the prevention, diagnosis and treatment of genetic diseases, namely, cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, auditory processing disorders (APD) and ...

drug delivery agents that facilitate delivery of pharmaceuticals, namely, engineered particles

medical and scientific research in the fields of gene therapy, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, cell therapy, therapeutic proteins, protein expression, protein delivery and drug delivery; services in the field of production of cell therapies namely, research in the field of gene editing technology featuring gene-editing and protein delivery; pharmaceutical research services; pharmaceutical drug development services; medical and scientific research for the treatment of genetic diseases and disorders
nvelop

General Information


Serial Number98072031
Word MarkNVELOP
Filing DateWednesday, July 5, 2023
Status645 - FINAL REFUSAL - MAILED
Status DateSaturday, July 13, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Servicespharmaceutical preparations for gene therapy and gene editing; drug delivery agents that facilitate delivery of pharmaceuticals, namely, drug delivery agents consisting of particles that facilitate delivery of a wide range of pharmaceuticals; drug carriers for medical use, namely, drug delivery agents in the form of engineered particles that facilitate the delivery of pharmaceutical preparations for delivering drugs to human organs; cell and gene therapy products for increasing protein expression in cells namely, engineered particles; pharmaceutical and biological preparations for delivering proteins into cells for the prevention, diagnosis and treatment of genetic diseases, namely, cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; pharmaceutical and biological preparations for delivering therapeutic proteins for treatment of cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, genetic diseases and disorders, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes
Goods and Servicesdrug delivery agents that facilitate delivery of pharmaceuticals, namely, engineered particles
Goods and Servicesmedical and scientific research in the fields of gene therapy, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, cell therapy, therapeutic proteins, protein expression, protein delivery and drug delivery; services in the field of production of cell therapies namely, research in the field of gene editing technology featuring gene-editing and protein delivery; pharmaceutical research services; pharmaceutical drug development services; medical and scientific research for the treatment of genetic diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, August 5, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, June 20, 2024
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, August 5, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNvelop Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02199

Trademark Events


Event DateEvent Description
Monday, June 10, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Saturday, July 8, 2023NEW APPLICATION ENTERED
Saturday, August 5, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 16, 2024ASSIGNED TO EXAMINER
Thursday, March 21, 2024NON-FINAL ACTION WRITTEN
Thursday, March 21, 2024NON-FINAL ACTION E-MAILED
Thursday, March 21, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, June 10, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 10, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, June 10, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 20, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 20, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 20, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, July 13, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Saturday, July 13, 2024FINAL REFUSAL WRITTEN
Saturday, July 13, 2024FINAL REFUSAL E-MAILED